Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal estrogen‑receptor‑positive breast cancer.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. All batches are manufactured under EU GMP guidelines and undergo rigorous release testing before shipment. This ensures consistent potency and safety for patients worldwide.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer.

Postmenopausal estrogen‑receptor‑positive breast cancer: reduces risk of disease recurrence and progression. Adjuvant therapy after surgery: helps prevent cancer return in eligible patients. Neoadjuvant treatment to shrink tumors before surgery: improves operability in selected cases.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching discomfort in joints or muscles. - Nausea: feeling of queasiness or urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Osteoporotic fractures: increased risk of bone breaks due to reduced bone density. - Pulmonary embolism: blockage of lung arteries causing sudden shortness of breath.

When prescribing Letrozole, clinicians should observe several safety considerations.

Bone health monitoring: assess bone mineral density regularly. Liver function monitoring: check hepatic enzymes before and during therapy. Lipid profile monitoring: evaluate cholesterol levels periodically. Contraindicated in pregnancy: letrozole is pregnancy category X and must not be used. Avoid use in premenopausal women: drug is ineffective and may cause ovarian stimulation. Store at room temperature: keep in the original pack, protect from moisture.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase letrozole exposure. - Estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering effect. - Tamoxifen: concurrent use may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): may modestly raise plasma levels. - Warfarin: potential alteration of INR, requiring closer monitoring. - Statins: increased risk of myopathy when combined. - SSRIs: may add to fatigue and dizziness.